#India #Mumbai #ADC Development #Piramal Pharma Solutions #IntoCell

Piramal Pharma Solutions Partners with IntoCell

Piramal Pharma Solutions, a renowned global Contract Development and Manufacturing Organization (CDMO), has officially announced its partnership with IntoCell, a prominent biotechnology company from Korea. This strategic collaboration is set to significantly expand Piramal's capabilities in bioconjugate development, particularly in the area of antibody-drug conjugates (ADCs).

Objectives of the Partnership

This partnership is built upon a Memorandum of Understanding (MOU) that focuses on enhancing both companies' pharmaceutical offerings. By leveraging IntoCell's proprietary drug-linker technologies, which are pivotal in ADC development, Piramal aims to strengthen its competitive standing in the bioconjugate market. The MOU allows IntoCell to explore various licensing opportunities for its innovative drug-linker technologies while enabling Piramal to enhance its service repertoire, particularly in ADC contract research and manufacturing.

Strengthening Capabilities

Piramal has a solid background in ADC development and manufacturing spanning over two decades. The collaboration will augment its existing payload-linker and bioconjugation technologies, allowing the delivery of a wider assortment of payload-linkers to its clients. This move is expected to significantly reduce development timelines for bioconjugates, giving Piramal a key advantage in this specialized field.

The joint efforts will center around leveraging technologies such as the OHPAS linker and several payload platforms, including Nexatecan and iso-Nexatecan based payloads. These technologies are vital for advancing the development of the next generation of ADCs, making them more stable and effective in terms of drug delivery.

Benefits for Clients

Through this partnership, clients will benefit from a more streamlined path from drug concept to clinical application. The integration of IntoCell's resources into Piramal's existing capabilities is aimed at accelerating the development processes, thereby improving the overall service offerings and competitiveness of Piramal Pharma Solutions.

Tae Kyo Park, CEO of IntoCell, expressed optimism about the collaboration, emphasizing a commitment to ensuring mutual success by amalgamating both companies' expertise in innovative drug development technologies. Peter DeYoung, CEO of Piramal Global Pharma, also highlighted the significant enhancement of capabilities this partnership brings, asserting that it positions Piramal as a key player in developing solutions for advancing ADC technology and improving patient outcomes globally.

About Piramal Pharma Solutions

Piramal Pharma Solutions is renowned for offering comprehensive development and manufacturing solutions throughout the drug lifecycle. With a global footprint across North America, Europe, and Asia, it provides a full spectrum of services ranging from drug discovery and clinical supplies to commercial manufacturing of Active Pharmaceutical Ingredients (APIs). Additionally, it specializes in developing bioconjugates and other complex pharmaceuticals, which positions it as a go-to partner for companies looking to innovate in drug delivery systems.

About IntoCell

IntoCell, listed in KOSDAQ, focuses on developing proprietary linker-payload technologies that enhance the stability and solubility of ADC payloads. Its innovative systems and libraries are designed to facilitate the creation of the next-generation ADCs, unlocking potential improvements in cancer treatment methodologies.

In conclusion, the partnership between Piramal Pharma Solutions and IntoCell stands as a testament to the ongoing evolution in bioconjugate technology, promising significant advancements that could redefine therapeutic approaches and improve patient care around the globe.